Discontinuation of Monthly Calls

Monthly CoVP calls will no longer be conducted. Calls will be scheduled as needed for relevant updates.

Please continue to monitor your communications for up-to-date information.
COVID-19 Updates

- On June 18th, CDC recommended to expand COVID-19 vaccination to children younger than 5 years of age. This decision now universally recommends COVID-19 vaccination for everyone 6 months and older. Kids under 5 can get either the Pfizer-BioNTech (3 dose) or Moderna (2 dose) primary vaccine series.

- On June 23rd, CDC recommended to expand the use of Moderna COVID-19 vaccines to include children ages 6 through 17 years. A (2 dose) series is recommended for this age group.

- June 28th, FDA’s VRPBAC met to discuss COVID_strain selection/future boosters.
  - Committee voted 19-2 in favor of including a SARS-CoV-2 omicron component in COVID-19 vaccines that would be used for boosters in the U.S.
  - FDA has advised manufacturers seeking to update their COVID-19 vaccines to develop modified vaccines that add an omicron BA.4/5 spike protein component to the current vaccine composition to create a two component (bivalent) booster vaccine, so that the modified vaccines can potentially be used starting in early to mid-fall 2022 (tentatively in October).

- Novavax Update
Interim Clinical Considerations Update for Pediatric COVID-19 Vaccines
Moderna Pediatric Schedule: People Who Are NOT Moderately or Severely Immunocompromised

### Moderna (6 months–5 years)
- **Dose 1** (primary) → **Dose 2** (primary)
- 4-8 weeks
- **0.25 mL (25 mcg)**

### Moderna (6–11 years)
- **Dose 1** (primary) → **Dose 2** (primary)
- 4-8 weeks
- **0.50 mL (50 mcg)**

### Moderna (12–17 years)
- **Dose 1** (primary) → **Dose 2** (primary)
- 4-8 weeks
- **0.50 mL (100 mcg)**
Pfizer-BioNTech Pediatric Schedule: People Who Are NOT Moderately or Severely Immunocompromised

**Pfizer-BioNTech (6 months–4 years)**
- **Dose 1** (primary) 3-8 weeks
- **Dose 2** (primary) At least 8 weeks
- **Dose 3** (primary)
- 0.2 mL (3 mcg)

**Pfizer-BioNTech (5–11 years)**
- **Dose 1** (primary) 3-8 weeks
- **Dose 2** (primary) At least 5 months
- **Dose 3** (booster)
- 0.2 mL (10 mcg)

**Pfizer-BioNTech (12–17 years)**
- **Dose 1** (primary) 3-8 weeks
- **Dose 2** (primary) At least 5 months
- **Dose 3** (booster)
- 0.3 mL (30 mcg)
# Moderna Pediatric Schedule: People Who ARE Moderately or Severely Immunocompromised

<table>
<thead>
<tr>
<th>Moderna</th>
<th>Dose 1 (primary)</th>
<th>Dose 2 (primary)</th>
<th>Dose 3 (primary)</th>
<th>Dose 1 (primary)</th>
<th>Dose 2 (primary)</th>
<th>Dose 3 (primary)</th>
<th>Dose 1 (primary)</th>
<th>Dose 2 (primary)</th>
<th>Dose 3 (primary)</th>
</tr>
</thead>
<tbody>
<tr>
<td>(6 months–5 years)</td>
<td>4 weeks</td>
<td>At least 4 weeks</td>
<td>0.25 mL (25 mcg)</td>
<td>4 weeks</td>
<td>At least 4 weeks</td>
<td>0.50 mL (50 mcg)</td>
<td>4 weeks</td>
<td>At least 4 weeks</td>
<td>0.50 mL (100 mcg)</td>
</tr>
<tr>
<td>(6–11 years)</td>
<td>0.50 mL (100 mcg)</td>
<td>0.25 mL (25 mcg)</td>
<td>0.50 mL (50 mcg)</td>
<td>0.50 mL (100 mcg)</td>
<td>0.50 mL (100 mcg)</td>
<td>0.50 mL (100 mcg)</td>
<td>0.50 mL (100 mcg)</td>
<td>0.50 mL (100 mcg)</td>
<td>0.50 mL (100 mcg)</td>
</tr>
<tr>
<td>(12–17 years)</td>
<td>0.50 mL (100 mcg)</td>
<td>0.50 mL (100 mcg)</td>
<td>0.50 mL (100 mcg)</td>
<td>0.50 mL (100 mcg)</td>
<td>0.50 mL (100 mcg)</td>
<td>0.50 mL (100 mcg)</td>
<td>0.50 mL (100 mcg)</td>
<td>0.50 mL (100 mcg)</td>
<td>0.50 mL (100 mcg)</td>
</tr>
</tbody>
</table>
Pfizer-BioNTech Pediatric Schedule: People Who ARE Moderately or Severely Immunocompromised

**Pfizer-BioNTech (6 months– 4 years)**
- **Dose 1** (primary) 3 weeks
- **Dose 2** (primary)
- **Dose 3** (primary) At least 8 weeks
- Dose 1 (booster) At least 3 months
- Dose 5 (2nd booster) At least 4 months

**Pfizer-BioNTech (5 years– 11 years)**
- **Dose 1** (primary) 3 weeks
- **Dose 2** (primary) At least 4 weeks
- **Dose 3** (primary) At least 3 months
- **Dose 4** (booster)

**Pfizer-BioNTech (12 years– 17 years)**
- **Dose 1** (primary) 3 weeks
- **Dose 2** (primary) At least 4 weeks
- **Dose 3** (primary) At least 3 months
- **Dose 4** (booster) At least 4 months

- Dose 1 (primary) 0.2 mL (3 mcg)
- Dose 2 (primary) 0.2 mL (10 mcg)
- Dose 3 (primary) 0.3 mL (30 mcg)
Schedule Resources


## Pfizer-BioNTech COVID-19 Vaccine Products

<table>
<thead>
<tr>
<th>Vial Cap Color</th>
<th>Dose (mRNA concentration)</th>
<th>Injection Volume</th>
<th>Dilution Required</th>
<th>Doses per Vial</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Product for ages 6 mons – 4 years</strong></td>
<td>3 mcg</td>
<td>0.2 mL</td>
<td>Yes—2.2 mL</td>
<td>10 (after dilution)</td>
</tr>
<tr>
<td><strong>Product for ages 5–11 years</strong></td>
<td>10 mcg</td>
<td>0.2 mL</td>
<td>Yes—1.3 mL</td>
<td>10 (after dilution)</td>
</tr>
<tr>
<td><strong>Product for ages 12 years and older</strong></td>
<td>30 mcg</td>
<td>0.3 mL</td>
<td>No</td>
<td>6</td>
</tr>
</tbody>
</table>

- **Vial Cap Color:** Maroon, Orange, Gray
- **Dose (mRNA concentration):** 3 mcg, 10 mcg, 30 mcg
- **Injection Volume:** 0.2 mL, 0.2 mL, 0.3 mL
- **Dilution Required:** Yes—2.2 mL, Yes—1.3 mL, No
- **Doses per Vial:** 10 (after dilution), 10 (after dilution), 6
Pfizer-BioNTech COVID-19 Vaccine Product for Ages 6 Months–4 Years

Vaccine may be discarded **12 hours** after dilution rather than **6 hours**.

Vial label states Age 2y to <5y but can be used in children ages 6 months–4 years.
## Moderna COVID-19 Vaccine Products

<table>
<thead>
<tr>
<th>Authorized Age group</th>
<th>6 months–5 years (primary series)</th>
<th>• 6–11 years (primary series)</th>
<th>• 12 years and older (primary series)</th>
<th>• 18 years and older (booster doses)</th>
<th>• 18 years and older (booster doses)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vial cap color</td>
<td>Dark blue</td>
<td>Dark blue</td>
<td>Red</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Label border color</td>
<td>Magenta</td>
<td>Purple</td>
<td>Light blue</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dose (mRNA concentration)</td>
<td>25 mcg</td>
<td>50 mcg</td>
<td>100 mcg (primary, age 12+); 50mcg (booster, age 18+)</td>
<td>0.5 mL (primary, age 12+); 0.25mL (booster, age 18+)</td>
<td></td>
</tr>
<tr>
<td>Injection volume</td>
<td>0.25 mL</td>
<td>0.5 mL</td>
<td>0.5 mL (primary, age 12+); 0.25mL (booster, age 18+)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dilution required</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Doses per vial</td>
<td>10</td>
<td>5</td>
<td>Maximum of 11</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Moderna COVID-19 Vaccine Product for Ages 6–11 Years

Labeled for “BOOSTER DOSES ONLY” but is authorized for:
• Primary doses in children ages 6–11 years
• Booster doses in adults ages 18 years and older
Product Resources

- Storage, handling, preparation, and administration job aids by product: [https://www.cdc.gov/vaccines/covid-19/info-by-product/index.html](https://www.cdc.gov/vaccines/covid-19/info-by-product/index.html)


- At-a-glance job aids
Vaccine Dosage: CDC’s Recommendation

- **CDC’S recommendation**: Children should receive the age-appropriate vaccine product and follow the schedule based on their age on the day of vaccination, regardless of their size or weight.

- If a person moves from a younger age group to an older age group during the primary series or between the primary series and receipt of the booster dose(s), they should receive the vaccine dosage for the older age group for all subsequent doses.

- FDA authorization allows for dosing options for certain age transitions. If these options occur, they are not considered errors and the doses “count”.
FDA allowance for Moderna age 5 to 6 years

Children who will turn from age 5 years to 6 years between doses in the primary series to receive, for any primary dose: (1) the Moderna COVID-19 Vaccine product authorized for children ages 6 months–5 years or (2) the Moderna COVID-19 Vaccine product authorized for children ages 6–11 years.

**Dose 1 (Age 5):**
- 0.25 mL (25 mcg) of the product for ages 6 months–5 years or
- 0.50 mL (50 mcg) of the product for ages 6–11 years

**Dose 2 (Age 6):**
- 0.25 mL (25 mcg) of the product for ages 6 months–5 years or
- 0.50 mL (50 mcg) of the product for ages 6–11 years
Children who will turn from age 11 years to 12 years between doses in the primary series to receive, for any primary dose: (1) the Moderna COVID-19 Vaccine product authorized for children ages 6–11 years or (2) the Moderna COVID-19 Vaccine product authorized for people ages 12 years and older.

**Dose 1 (Age 11):**
- 0.50 mL (50 mcg) of the product for ages 6–11 years
- 0.50 mL (100mcg) of the product for ages 12 years and older

**Dose 2 (Age 12):**
- 0.50 mL (50 mcg) of the product for ages 6–11 years
- 0.50 mL (100mcg) of the product for ages 12 years and older
FDA allowance for Pfizer-BioNTech age 4 to 5 years

**Scenario 1**: A 2-dose primary series using the product for people ages 5–11 years (orange cap)

**Dose 1 (Age 4):**
0.2 mL (10 mcg) of the product for ages 5–11 years

**Dose 2 (Age 5):**
0.2 mL (10 mcg) of the product for ages 5–11 years
Scenario 2: A 3-dose primary series initiated with the product for ages 6 months–4 years. Dose 2 and 3 may be with: the product for ages 6 months–4 years or the product for ages 5–11 years.

- **Dose 1 (Age 4):**
  0.2 mL (3 mcg) of the product for ages 6 months–4 years

- **Dose 2 (Age 4 or 5):**
  0.2 mL (3 mcg) of the product for ages 6 months–4 years, or
  0.2 mL (10 mcg) of the product for ages 5–11 years

- **Dose 3 (Age 5):**
  0.2 mL (3 mcg) of the product for ages 6 months–4 years, or
  0.2 mL (10 mcg) of the product for ages 5–11 years
Aging up Resources


Interchangeability

- COVID-19 vaccines are not interchangeable.

- The same mRNA vaccine product should be used for all doses of the primary series.

- In exceptional situations in which the mRNA vaccine product administered for a previous dose(s) of the primary series cannot be determined or is not available, either age-appropriate available mRNA COVID-19 vaccine product may be administered at a minimum interval of 28 days between doses to complete the mRNA COVID-19 primary vaccination series.
Mixed Series For Children Ages 6 months–4 Years

- Children ages 6 months–4 years who receive different mRNA products for the first 2 doses of an mRNA COVID-19 vaccine series should receive a third dose of either mRNA vaccine 8 weeks after the second dose to complete the 3-dose primary series.
Mixed Series For Children Ages 6 months–4 Years

- **Scenario 1:**
  - **Dose 1:** 0.20 mL (3mcg) of the Pfizer-BioNTech product for ages 6 months through 4 years
  - **Dose 2:** 0.25 mL (25mcg) of the Moderna product for ages 6 months through 5 years
  - **Dose 3:** 0.20 mL (3mcg) of the Pfizer-BioNTech product for ages 6 months through 4 years **or** 0.25 mL (25mcg) of the Moderna product for ages 6 months through 5 years
Mixed Series For Children Ages 6 months–4 Years

- Scenario 1:

  Dose 1:
  0.25 mL (25mcg) of the Moderna product for ages 6 months through 5 years

  Dose 2:
  0.20 mL (3mcg) of the Pfizer-BioNTech product for ages 6 months through 4 years

  Dose 3:
  0.20 mL (3mcg) of the Pfizer-BioNTech product for ages 6 months through 4 years
  --or--
  0.25 mL (25mcg) of the Moderna product for ages 6 months through 5 years
Preventing Vaccine Administration Errors

- Clinical guidance for errors:
  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#appendix-c

- Handout:
  https://www.cdc.gov/vaccines/hcp/admin/downloads/vaccine-administration-preventing-errors.pdf
Interim Clinical Considerations

- Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html

- FAQs for the Interim Clinical Considerations: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/faq.html
Clinical Resources

- US COVID-19 Vaccine Product Information:
  https://www.cdc.gov/vaccines/covid-19/info-by-product/index.html
CT WiZ/VAMS Update
CT WiZ Updates

The Recommender in CT WiZ

New Immunization Program Webpage Coming Soon!

Version 1.0
6/30/2022
• Effective 7/1/2022, the CT WiZ law was amended mandating all vaccinating providers to report electronically to CT WiZ.

• DPH will help VAMS clinics transition to CT WiZ. Submit a helpdesk ticket with your PIN to start the process.

• DPH will schedule a call to review the transition process with your clinic.
COVID-19 Vaccine Updates

• CT WiZ has been updated with the new young pediatric COVID-19 vaccines:
  • Vaccines Supplied By CT_CVP_62422.pdf

Please ensure you enter the correct COVID-19 vaccines.
CT WiZ Recommender

• When there is a new vaccine recommendation or a change in the vaccine schedule, it requires the **CT WiZ Recommender to be updated in a new CT WiZ release.**

  • If you see a valid dose with an ! *(invalid)*, when the Recommender is updated, the ! will disappear and the dose will display as valid.

• Tip: Print the Full immunization record until the Recommender is updated. (The COVID-19 only record only displays valid doses.)
New Immunization Program Webpage!

New WEBSITE COMING SOON
Question and Answers

To ask a question, please raise your hand using the hand icon on your screen, type your question in the chat box or if you are on the phone press *6 to unmute yourself.

If you have additional questions after the meeting, please feel free to email them to DPH.Immunizations@ct.gov

You can fill out a help desk ticket by visiting https://dph-cthelpdesk.ct.gov/Ticket